New analyses of Phase II ‘signal finding’ data supports the continued development of Blautix in larger studies as a novel treatment for irritable bowel syndrome (IBS). There is estimated to be 25-45m IBS patients in the US, but treatment options for IBS–Constipation and IBS-Diarrhoea are limited, and there are currently no approved therapy for IBS patients with mixed symptoms, representing a significant market opportunity. We believe data should be viewed with interest by potential partners, and ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
New Blautix Phase II data adds further support
- Published:
24 May 2021 -
Author:
Edward Thomason -
Pages:
3
New analyses of Phase II ‘signal finding’ data supports the continued development of Blautix in larger studies as a novel treatment for irritable bowel syndrome (IBS). There is estimated to be 25-45m IBS patients in the US, but treatment options for IBS–Constipation and IBS-Diarrhoea are limited, and there are currently no approved therapy for IBS patients with mixed symptoms, representing a significant market opportunity. We believe data should be viewed with interest by potential partners, and ....